A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00197067
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : June 2, 2017
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : April 26, 2005
  Actual Study Completion Date : April 26, 2005